Corbus Pharmaceuticals Presents Results Of Two Pre-Clinical Studies On Its Anti-αVβ8 Monoclonal Antibody At The 2023 SITC Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) presented results from two pre-clinical studies on its CRB-601 anti-aVb8 integrin monoclonal antibody at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The studies demonstrated robust pre-clinical anti-tumor activity of CRB-601, alone and in combination with anti-PD-1 therapy. The company plans to submit an Investigational New Drug application for CRB-601 by the end of 2023 and expects to initiate its Phase 1 study by the end of June 2024.
November 02, 2023 | 12:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corbus Pharmaceuticals' pre-clinical studies on CRB-601 showed promising results, which could potentially boost investor confidence in the company's research and development capabilities.
The positive pre-clinical results for Corbus Pharmaceuticals' CRB-601 could potentially increase investor confidence in the company's research and development capabilities. This could lead to increased demand for the company's stock, potentially driving its price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100